INMUNOSUN-SOGUG trial: A prospective phase II study to assess the efficacy and safety of sunitinib as second-line (2L) treatment in patients (pts) with metastatic renal cell cancer (RCC) who received immunotherapy-based combination upfront.

Enrique Grande,Teresa Alonso-Gordoa,Oscar Reig Torras,Emilio Esteban,Daniel Castellano,Xavier Garcia-del-Muro,Maria Jose José Mendez Vidal,Jesús García-Donas,Jose Angel Arranz,Cristina Suarez Rodriguez

INMUNOSUN-SOGUG trial: A prospective phase II study to assess the efficacy and safety of sunitinib as second-line (2L) treatment in patients (pts) with metastatic renal cell cancer (RCC) who received immunotherapy-based combination upfront.

2020

Enrique Grande
Teresa Alonso-Gordoa
Oscar Reig Torras
Emilio Esteban
Daniel Castellano
Xavier Garcia-del-Muro
Maria Jose José Mendez Vidal
Jesús García-Donas
Jose Angel Arranz
Cristina Suarez Rodriguez

5060Background: Immunotherapy (IO)-based combinations have replaced tyrosine kinase inhibitors (TKI) as standard upfront treatment of metastatic RCC pts. Selection of 2L treatment after progression...

Keywords:

Oncology
in patient
second line
Immunotherapy
Internal medicine
Metastatic renal cell cancer
Phases of clinical research
Pathology
Sunitinib
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations